News Center

Home page

Peak Report

News reports

Announcement on the Project of Annual Production of 2 billion Solid Preparations by Peak Pharmaceutical

Release time:

2020-08-05

Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: Pro 2018-024

Bond Abbreviation: 13 Spike 02 Bond Code: 122344

Announcement of Zhejiang Jianfeng Group Co., Ltd.

on Jianfeng Pharmaceutical's Annual Production of 2 billion Solid Preparations

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assume individual and joint responsibility for the truthfulness, accuracy and completeness of its contents.

Important Content Note:

l Project Name: 2 billion Pieces of Solid Preparation Project

l Annual Output of Jinxi Production Base of Jianfeng Pharmaceutical Industry Investment Amount: The total planned investment of the project is 501.46 million yuan, and the source of funds is self-raised.

l Special Risk Reminder: The construction period of this project is relatively long. With the continuous advancement of the domestic medical system reform

, the hospital's strict control of drug proportion, sunshine procurement and quantity procurement, secondary bargaining, prescription outflow, etc. continue to deepen, and drug prices show a downward trend. In addition, trade protectionism is on the rise and competition in the international market will become more intense, profitability may be affected and there is a risk that project returns will not meet expectations.

1. Project Investment Overview

According to the company's strategic policy of "strengthening the main business through cooperation and innovation, standardizing science and seeking development", Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical Co., Ltd."), a subsidiary of the company, is based on the development strategy of the company and relevant regulations of national pharmaceutical production, in order to further improve the solid preparation production capacity of Jianfeng Pharmaceutical, it is planned to acquire about 78 mu of land on the north side of the existing factory area of Jianfeng Pharmaceutical in Jinhua Economic Development Zone, set up a new preparation factory area, and build a preparation manufacturing platform that meets the requirements of GMP in Europe and America. The construction of the project with an annual output of 2 billion solid preparations in Jinxi Production Base of Jianfeng Pharmaceutical includes two preparation workshops and supporting storage, quality inspection, public works, etc. After the completion of the preparation workshop 1 to form an annual production capacity of 2 billion pieces of solid preparations, while reserving the preparation workshop 2 for later development.

On August 3, 2018, the fifth meeting of the tenth board of directors of the company reviewed and approved the "Proposal on the Project of 2 billion Solid Preparations per Year in Jinxi Production Base of Jianfeng Pharmaceutical", and agreed to invest in the construction of Jinxi Production Base with an annual output of 2 billion solid preparations.

In accordance with the "Shanghai Stock Exchange Stock Listing Rules", "Articles of Association" and other relevant regulations, this project investment is within the decision-making authority of the company's board of directors and does not need to be submitted to the company's shareholders meeting for approval. Related party transactions do not constitute a major asset reorganization as stipulated in the "Administrative Measures for the Major Asset Reorganization of Listed Companies.

Basic Information of 2. Investment Subject

(I) Investment Subject: Zhejiang Jianfeng Pharmaceutical Co., Ltd.

(II) Enterprise Nature: Other Limited Liability Company

(III) Registered Capital: 198.53 million yuan

(IV) Registered Address: legal Representative of (V) Company

, 2nd Floor, X02 Office Quality Inspection Building, No. 58 Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province: Jiang Xiaomeng

(VI) Scope of Business: Drug Research and Development and Production (Operating with Valid License); Annual recovery: 8 tons of isopropanol, 76 tons of ethanol, 40 tons of toluene, 409 tons of dichloromethane, and 11 tons of ethyl acetate (operating with valid licenses); imported raw and auxiliary materials for production and scientific research; imported machinery and equipment, instruments and spare parts. (Projects subject to approval according to law can only be operated after approval by relevant departments)

(VII) Financial Situation: As of December 31, 2017, Jianfeng Pharmaceutical has total assets of 1,193.4823 million yuan and net assets of 378.2793 million yuan attributable to owners of the parent company. In 2017, it will realize operating income of 1,337.522 million yuan, operating profit of 50.6395 million yuan and net profit of 37.6413 million yuan attributable to owners of the parent company. Basic Information of

3. Investment Project

(I) Project Name: Jianfeng Pharmaceutical Jinxi Production Base Annual Output of 2 billion Pieces of Solid Preparation Project

(II) to Form Production Scale after Completion: Annual Output of 2 billion Pieces of Solid Preparation

(III) Total Building Area: 63352 m2

Total (IV) Investment: the total investment is 501.46 million yuan, of which the investment in fixed assets is 481.98 million yuan and the working capital is 19.48 million yuan.

(V) construction progress: after the conditions are met, the project construction period is 2 years. The main content of the

(VI) project: the annual output of 2 billion pieces of solid preparations in Jinxi production base of Jianfeng pharmaceutical includes two preparation workshops and supporting storage, quality inspection, public works, etc. After the completion of the preparation workshop 1 to form an annual production capacity of 2 billion pieces of solid preparations, while reserving the preparation workshop 2 for later development.

Impact of 4. Investment Project on Listed Companies

Jianfeng Pharmaceutical has rich experience in preparation research and development, production and sales. This project will further improve the construction of generic preparation production base, promote the upgrading of preparation industry and enhance the comprehensive competitiveness of the company's pharmaceutical sector. Under the background of preparation internationalization and continuous improvement of generic drug consistency evaluation, this project takes international generic drugs as the entry point, which is of great significance to improve the equipment level and manufacturing capacity of Jianfeng pharmaceutical preparations, expand the industrial scale, optimize the product structure and participate in international competition, and will have a positive impact on the future development of the company.

Risk Analysis of 5. Investment Project

(I) Market Risk

The construction period of this project is relatively long. With the continuous advancement of domestic medical system reform, hospitals continue to deepen the 120 of # in strict control of drug proportion, sunshine procurement and quantity procurement, secondary bargaining, prescription outflow, etc, drug prices are on a downward trend; in addition, trade protectionism is on the rise and competition in the international market will become more intense, which may affect profitability, and there is a risk that the project revenue will not meet expectations .

(II) Project Construction and Management Technical Risks

Project is still in the preliminary preparation stage, and land acquisition and environmental assessment have not yet been completed. With the adjustment of relevant national industrial policies and urban planning, the project construction There are certain uncertainties in the content, cycle and process. After the project is completed and put into production, there is a possibility that the expected goals may not be achieved in terms of product process improvement and cost control, and there are certain management and technical risks.

(III) Capital Risk

The total investment of this project is relatively large. The project is invested through self-raised funds. There is uncertainty as to whether the funds can be in place on schedule. The fund raising and credit policy changes in the construction process, The smoothness of financing channels will make the company bear certain capital risks.

(IV) Approval Risk

After the project is reviewed and approved by the board of directors, the project construction still needs to go through compliance procedures such as safety assessment and environmental assessment, and is still in the process of approval. Therefore, whether the project can be finally implemented, There is still some uncertainty about the progress after implementation.

6. Reference Document

Resolution of the Fifth Meeting of the Tenth Board of Directors

is hereby announced.

Zhejiang Jianfeng Group Co., Ltd. Board of Directors

August 3, 2018

More information

Spike New Drug Approved for Registration

On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)

2020

07-22

Peak International Trade was rated as "excellent delivery warehouse" by the big business"

On April 12, the 2019 Dalian Commodity Exchange Industrial Products Delivery Work Summary Meeting was held in Dalian. Jianfeng International Trading Company was rated as "2018 (Industrial Products) Excellent Delivery Warehouse" and Ruan Weihang, an employee of the International Trading Company, was rated as "2018 (Industrial Products) Excellent Futures Specialist in Designated Delivery Warehouse". The delivery link is the bridge link between the futures and cash markets, an important area of risk prevention and control in the futures market, and a strong guarantee for the smooth operation and function of the market. Since obtaining the qualification of PVC delivery warehouse in 2009, the chemical warehousing and logistics business of international trading company has developed steadily. In terms of management, the international trading company strictly follows the various systems of the Dalian Commodity Exchange to implement warehouse-in and warehouse-in management. The management level has been improved year by year. Broken packages have been handled on the spot, and the loss of goods has been greatly reduced. The management goal of daily clearing has been achieved, and standardized operations have been achieved; in terms of business marketing, the futures business has driven the gradual development and growth of the spot business, futures varieties have developed from a single PVC variety to four varieties of PVC, PP, PE and plywood. The business volume has increased year by year and has exceeded 500000 tons. The operation volume can exceed 2500 tons/day; In terms of customer service, from zero experience in futures business to now, customer reputation has increased year by year, and customer complaints have gradually decreased. The annual excellent delivery warehouse of the judges is the full affirmation of Dalian Commodity Exchange on the functions of international trading companies, market satisfaction, futures management level and standardization of warehouse daily management. Lou Chunming, general manager of the international trading company, said that the international trading company will implement

2020

07-31

Spike New Drug Approved for Registration

2020

07-30

Peak Cement Won the Bid for National Key Project Daye Peak Becomes Huang-Huang Railway Supplier

On March 19, Daye Jianfeng Cement Company officially received a notice from China Railway Construction Material Collection Center that the company was shortlisted for the new Huang (Mei) Huang (Zhou) railway project in the Hubei section of the Shanghai-Chengdu high-speed railway along the Yangtze River in the second place, and obtained the right to supply the 6th package of cement. This is the first stick undertaken by Daye Jianfeng in 2019, and it is also the second time to enter the high-speed rail project after the Wu (Han) Jiu (Jiang) high-speed rail. The Huanghuang high-speed railway is a component of the "eight vertical and eight horizontal" high-speed railway network in the "National Medium and Long-term Railway Network Plan". It is a component of the Wuhan-Hangzhou and Beijing-Hong Kong-Kowloon high-speed railway network. It has a total length of 125 kilometers and a design speed of 350 kilometers per hour. It will start construction at the end of 2018. It will be opened to traffic in 2021. In addition to the characteristics of large demand for high-speed railway and highway projects, the project time span is long and the product quality requirements are high, especially the high-speed railway project has extremely strict requirements on the alkali content of cement. After participating in the bidding, Yuan Xianming, executive deputy general manager of Daye Peak, organized production, quality control, procurement and other relevant departments for many times to carry out tests on the production of low-alkali cement and adjust the proportion of raw materials. The quality control department also sent samples to the provincial professional inspection department for comparative inspection to ensure product stability. The marketing department carefully checked the details of the tender, strictly checked and repeatedly deduced the bid price. Finally, with the full cooperation of all departments, the successful bidding was passed, finalist Huang-Huang high-speed rail project. It is understood that as the country continues to increase investment in infrastructure transportation construction, daye peak adjusted its work direction at the end of 2018, requiring marketing work in 2019 to focus on key projects.

2020

07-31

Daye Peak Opens "Standard Year"

After the 2019 overhaul ended in early March, Daye Jianfeng Cement Company immediately launched the "Standard Year" activity to carry out standardized rectification in view of a series of defects and problems in the daily management process. The goal of the "Standard Year" activity is to target specific issues that affect employees' work efficiency and safe and environmentally friendly production. Through the formulation of institutionalized work standards, further standardize employees' various operations, improve operational efficiency, and improve grassroots management execution, so as to achieve The purpose of improving the company's image, reducing costs, improving efficiency, and increasing benefits. In order to ensure the smooth progress of the activities, daye peak has set up a promotion team headed by general manager Zhang fengliang to be responsible for the overall promotion of the "standard year" activities, mainly including revising the activity plan, summarizing the standardized implementation standards of various departments, implementing the plan, supervising the implementation progress, evaluating the implementation effect, collecting suggestions and opinions in the implementation process, etc. Based on the foundation, aiming at the details and solving problems is a major feature of Daye peak's "standard year" activity. For example, the "Flange Sealing Operation Standard", which is currently being tried out, not only puts forward standardization requirements for such a "trivial matter" in equipment management as flange sealing, but also attaches "model" photos to make it clear to mechanics What should be done and what should be done. However, this "small standard" aims at three problems: leakage at the production site, extensive mechanic work and waste of materials. Once it becomes the behavior habit of employees, the hygiene and cost control at the production site are bound to be improved. It is understood that Daye peak "standard year" activities plan to continue for three years to promote, activities

2020

07-22

Daye Peak Opens "Standard Year"

2020

07-31

< 1...31 32 33...61 > 跳转到页